Sep 2026
First-in-human phase I study of DT-9081, a selective EP4 receptor antagonist, in advanced solid tumors.
R. Galot, Z. Castel-Ajgal, N. Kotecki et al.
· Investigational new drugs · 0 citations
2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
Sep 2026
Discovery of DT-9081, a Potent and Orally Bioavailable Small Molecule Antagonist of the EP4 Receptor for the Treatment of Solid Cancers
The EP4 receptor (EP4R) has emerged as a promising target in immuno-oncology due to its role in modulating tumor immunity and inflammation. Here, we describe the discovery and preclinical development of DT-9081, a clinical candidate EP4R-antagonist that has completed a phase I monotherapy trial for the treatment of s...
Anne-Laure Blayo, G. Hommet, Mickael Fer et al.
· Journal of Medicinal Chemist... · 1 citation